On 16 November 2026, Sandoz announced the US launch of Enzeevu® (aflibercept-abzv) 2 mg, biosimilar to Regeneron/Bayer’s Eylea®, 2 mg. Enzeevu® is available in a pre-filled syringe and is approved for the treatment of various retinal diseases including nAMD, macular oedema following retinal vein occlusion, diabetic retinopathy and diabetic macular oedema.
Sandoz has entered into a multi-year private-label agreement for Enzeevu®, under which Sandoz will manufacture Enzeevu® for commercialisation under a private label beginning in mid-2027.
Enzeevu® was approved by the FDA in August 2024. In the same month, Regeneron commenced BPCIA litigation against Sandoz in the US District Court for the District of New Jersey asserting infringement of 46 US patents relating to aflibercept. A settlement of the BPCIA litigation was announced on 9 September 2025, with Sandoz permitted to launch its aflibercept biosimilar in Q4 2026.
Enzeevu® is the third aflibercept biosimilar on the US market, following the launch of Amgen’s Pavblu® in October 2024 (following the US Court of Appeals’ denial of Regeneron’s injunction application) and Biocon’s Yesafili™ in August 2026 (under an April 2025 settlement).
A stream of further upcoming aflibercept biosimilar launches is expected in the US resulting from litigation settlements, including Formycon/Klinge’s Ahzantive® (approved June 2024, due to launch Q4/2026), Celltrion’s Eydenzelt® (approved October 2025, due to launch Q4/2026), Alvotech/Teva’s AVT06 (due to launch Q4/2026, subject to regulatory approval), and Samsung Bioepis’ Opuviz® (approved May 2024, due to launch from January 2027).
